

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5506114

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PURDUE PHARMA	12/03/2018
RECEIVING PARTY DATA	
Name:	PURDUE PHARMA L.P.
Street Address:	ONE STAMFORD FORUM
City:	STAMFORD
State/Country:	CONNECTICUT
Postal Code:	06901-3431
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	16282858
Application Number:	16282876
Application Number:	16399571
Application Number:	16399574
Application Number:	16399580
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-371-2600
Email:	MBODENSTEIN@sternekessler.com, XSHEN@sternekessler.com, shylton@sternekessler.com, ttopssecretary2@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	1861.4140006, 7, 8, 9, A
NAME OF SUBMITTER:	MATTHEW S. BODENSTEIN
SIGNATURE:	/Matthew S. Bodenstein/
DATE SIGNED:	05/03/2019
Total Attachments: 5	
source=1861-Assignment-from-Purdue-Pharma-to-Purdue-Pharma-LP#page1.tif	

source=1861-Assignment-from-Purdue-Pharma-to-Purdue-Pharma-LP#page2.tif

source=1861-Assignment-from-Purdue-Pharma-to-Purdue-Pharma-LP#page3.tif

source=1861-Assignment-from-Purdue-Pharma-to-Purdue-Pharma-LP#page4.tif

source=1861-Assignment-from-Purdue-Pharma-to-Purdue-Pharma-LP#page5.tif

PATENT

REEL: 049071 FRAME: 0559

CONFIRMATORY PATENT ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, **Purdue Pharma**, a Canadian limited partnership, having an office and place of business at 575 Granite Court, Pickering, Ontario, L1W 3W8, Canada (hereafter referred to as the "Assignor"), hereby confirms the sale and assignment to **Purdue Pharma L.P.**, a Delaware limited partnership, having an office and place of business at One Stamford Forum, Stamford, CT, 06901-3431, USA (hereafter referred to as the "Assignee"), of its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), including the right to sue for past infringement and to collect for all past, present and future damages, as follows,

WHEREAS, Assignor has assigned and transferred to Assignee on December 3rd, 2018, all right, title, and interest in and to certain inventions, patents, and applications (the "Assigned Patents"), including the patents and applications set forth in **Schedule I** attached hereto; and

WHEREAS, a recordable document is needed to demonstrate the assignment of the Assigned Patents noted in the attached **Schedule 1**;

NOW, THEREFORE, for good and valuable consideration, Assignor does hereby confirm that Assignor assigned and transferred to Assignee, its representatives, successors, and assigns, its entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, in the United States, (a) in the Assigned Patents, in any and all applications thereon, and in any and all Letters Patent(s) therefor, and (b) in any and all patents and applications in the United States that claim the benefit of the Assigned Patents (a), including continuing applications (continuation, divisional, or continuation-in-part), reissues, extensions, renewals and reexaminations of the patent applications or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and (c) in any and all inventions described in the Assigned Patents listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such Assigned Patents, and that are derivable from any and all continuing applications (continuation, divisional, or continuation-in-part), reissues, extensions, renewals and reexaminations of such patents and patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable; all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, extension, renewal, reexamination, or corresponding applications thereof, and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.


The Assignor hereby grants the Assignee the power to insert in this assignment, including the attached Schedule 1, any further information regarding the patents and patent applications so identified in such Schedule 1 that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

[Remainder of Page Intentionally Left Blank]

SIGNED on behalf of said ASSIGNOR (Purdue Pharma),

PURDUE PHARMA

By: Purdue Pharma Inc. (an Ontario corporation),
its general partner

By:  _____

Name: David Pridemore

Title: President and CEO

Date: December 3, 2018 _____

SIGNED on behalf of said ASSIGNEE (Purdue Pharma L.P.),

PURDUE PHARMA L.P.

By: Purdue Pharma Inc. (a New York corporation),
its general partner

By: _____

Name:

Title:

Date: _____

[Confirmatory Patent Assignment]

PATENT
REEL: 049071 FRAME: 0562

SIGNED on behalf of said ASSIGNOR (**Purdue Pharma**),

PURDUE PHARMA

By: Purdue Pharma Inc. (an Ontario corporation),
its general partner

By: _____

Name:

Title:

Date: _____

SIGNED on behalf of said ASSIGNEE (**Purdue Pharma L.P.**),

PURDUE PHARMA L.P.

By: Purdue Pharma Inc. (a New York corporation),
its general partner

By: _____

Name: Paul Medeiros

Title: Senior Vice President

Date: December 3, 2018

PATENT

[Confirmatory Patent Assignment] **REEL: 049071 FRAME: 0563**

SCHEDULE 1 – PATENTS AND PATENT APPLICATIONS

Patent No.	Application Serial No.	Priority Date	Status	Title
	U.S. 62/122,847	October 31, 2014	Provisional Application (Expired)	
U.S. 9,974,752	14/928,276	October 31, 2014	Issued May 22, 2018	Methods and compositions particularly for treatment of attention deficit disorder
U.S. 10,111,839 B2	15/958,413	October 31, 2014	Issued October 30, 2018	Methods and compositions particularly for treatment of attention deficit disorder
	16/120,900	October 31, 2014	Application	Methods and compositions particularly for treatment of attention deficit disorder
	16/120,999	October 31, 2014	Application	Methods and compositions particularly for treatment of attention deficit disorder
	16/185,730	October 31, 2014	Application	Methods and compositions particularly for treatment of attention deficit disorder
	16/195,418	November 19, 2018	Application	Methods and Compositions Particularly for Treatment of Attention Deficit Disorder